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Abstract
The N-terminal/conserved region 1 (CR1) portion of the human adenovirus (Ad) 5 E1A protein was previously shown to inhibit growth
in the simple eukaryote Saccharomyces cerevisiae. We now demonstrate that the corresponding regions of the E1A proteins of Ad3,-4,
-9,-12, and -40, which represent the remaining five Ad subgroups, also inhibit yeast growth. These results suggest that the E1A proteins of
all six human Ad subgroups share a common cellular target(s) conserved in yeast. Growth inhibition induced by either full-length or the
N-terminal/CR1 portion of Ad5 E1A was relieved by coexpression of the E1A binding portions of the mammalian p300, CBP, and pCAF
acetyltransferases. Similarly, growth inhibition by the N-terminal/CR1 portions of the other Ad E1A proteins was suppressed by expression
of the same regions of CBP or pCAF known to bind Ad5 E1A. The physical interaction of each of the different Ad E1A proteins with CBP,
p300, and pCAF was confirmed in vitro. Furthermore, deletion of the gene encoding yGcn5, the yeast homolog of pCAF and a subunit of
the SAGA transcriptional regulatory complex, restored growth in yeast expressing each of the different Ad E1A proteins. This indicates that
the SAGA complex is a conserved target of all Ad E1A proteins. Our results demonstrate for the first time that the p300, CBP, and pCAF
acetyltransferases are common targets for the E1A proteins of all six human Ad subgroups, highlighting the importance of these interactions
for E1A function.
© 2003 Elsevier Inc. All rights reserved.
Introduction
The proteins encoded by the human adenovirus (Ad)
type 5 early region 1A (E1A) gene function as potent reg-
ulators of cell growth and gene expression (Bayley and
Mymryk, 1994; Gallimore and Turnell, 2001; Frisch and
Mymryk, 2002). Despite the intensive study of Ad5 E1A,
relatively little is known about the E1A proteins of the other
five human Ad subgroups. Comparison of the sequences of
E1A from multiple Ad serotypes has identified four discrete
regions with a high degree of sequence conservation that
have been designated conserved regions (CR) 1, 2, 3, and 4
(Avvakumov et al., 2002). CR1 spans residues 42–72 of
Ad5 E1A. In the currently known E1A protein sequences,
CR1 is the most highly conserved, with an average identity
of 59% with respect to Ad5 E1A, whereas the N-terminal
portions share about 26% average identity with Ad5 E1A
(Avvakumov et al., 2002).
The N-terminal/CR1 portion of Ad5 E1A is known to
interact with several transcriptional coactivators, including
the acetyltransferases pCAF (Reid et al., 1998), CREB
Binding Protein (CBP), and related family member p300
(Eckner et al., 1994; Arany et al., 1995; Lundblad et al.,
1995). Interaction with CBP and p300 appears to be re-
quired for E1A-induced progression from the G1 phase into
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the S phase of the cell division cycle (Howe et al., 1990;
Wang et al., 1991), E1A-mediated repression of enhancer-
activated gene transcription (Jelsma et al., 1989; Rochette-
Egly et al., 1990) and transformation in cooperation with
activated ras (reviewed in Bayley and Mymryk, 1994). In
addition to Ad5 E1A (subgroup C), Ad12 E1A (subgroup
A) is known to bind p300 and CBP (Wang et al., 1993;
Dorsman et al., 1997). It is not known if Ad12 E1A interacts
with pCAF or whether any of the E1A proteins of the other
Ad subgroups can interact with p300, CBP, or pCAF.
Genetic studies in the budding yeast Saccharomyces cer-
evisiae have demonstrated that one or more cellular targets
of the N-terminal/CR1 portion of Ad5 E1A are conserved in
this simple eukaryote. When introduced into many haploid
strains of S. cerevisiae, this fragment of Ad5 E1A inhibits
growth, leading to an accumulation of cells in the G1 phase
of the cell cycle (Miller et al., 1995). Growth inhibition by
this fragment of E1A requires the yeast Spt-Ada-Gcn5-
acetyltransferase (SAGA) complex, but is not directly re-
lated to transcriptional activation by E1A (Kulesza et al.,
2002; Shuen et al., 2002). Indeed, the N-terminal/CR1 por-
tion of E1A can physically interact with at least two com-
ponents of the SAGA complex in yeast: yGcn5, the yeast
homolog of pCAF (Shuen et al., 2002), and Tra1, the yeast
homolog of TRRAP (Kulesza et al., 2002).
In this study, we show for the first time that the SAGA
complex in yeast and the mammalian p300, CBP, and
pCAF acetyltransferases are conserved targets for the E1A
proteins of all six human subgroups. These observations
highlight the importance of these interactions for E1A
function.
Results and discussion
Ad5 E1A-mediated inhibition of yeast growth can be
suppressed by portions of CBP or p300 known
to interact with Ad5 E1A
Expression of the Ad5 E1A protein suppresses growth in
many haploid strains of S. cerevisiae (Handa et al., 1987;
Wada et al., 1990; Miller et al., 1995). Inhibition of growth
is often determined visually by comparing the size of yeast
colonies expressing E1A with those of yeast transformed
with a control expression vector. The N-terminal/CR1 and
CR3 regions of Ad5 E1A can independently mediate growth
inhibition in yeast (Shuen et al., 2002). It has been shown
previously that expression of mammalian receptor for acti-
vated C kinase 1 (RACK1) can restore growth to yeast
expressing Ad5 E1A, presumably via a direct physical in-
teraction with the growth inhibitory N-terminal/CR1 do-
main (Sang et al., 2001). We reasoned that other mamma-
lian proteins known to interact with this region of Ad5 E1A
might similarly function to suppress growth inhibition. The
coexpressed mammalian protein might compete with an
endogenous yeast regulatory protein for interaction with
E1A, thus freeing the yeast cellular protein to perform its
normal function. To test this, we constructed a panel of
vectors expressing portions of CBP (Fig. 1A), a well char-
acterized mammalian protein targeted by Ad5 E1A. Yeast
expressing full-length Ad5 E1A and a fragment of CBP
spanning residues 1679–1891 grew rapidly as compared to
yeast expressing only Ad5 E1A or Ad5 E1A and fragments
spanning the remaining portions of CBP (Fig. 1B). Impor-
tantly, the region of CBP encompassed by residues 1679–
1891 has been shown to physically interact with Ad5 E1A
(Arany et al., 1995). Western blot analysis determined that
restoration of growth was not related to decrease in the level
of expression of the Ad5 E1A protein in response to CBP
expression (Fig. 1C). The corresponding portion of the CBP
related protein p300, which is also known to bind Ad5 E1A
(Eckner et al., 1994), similarly suppressed growth inhibition
by Ad5 E1A (Fig. 1D). Neither the CBP nor p300 fragment
that restored growth to yeast expressing Ad5 E1A had any
effect on growth inhibition by the unrelated Ad2 E1B 55-
kDa protein, suggesting that their effects on growth are
specific for yeast expressing E1A (data not shown).
Unfortunately, E1A mutants containing small deletions
that impair p300 or CBP binding in mammalian cells do not
efficiently suppress yeast growth (Miller et al., 1995). For
this reason they could not be tested to further confirm that a
direct interaction with CBP is required for restoration of
yeast growth. However, our observation that only fragments
of CBP or p300 known to bind Ad5 E1A can specifically
suppress yeast growth inhibition mediated by Ad5 E1A
suggests that growth restoration results from a physical
interaction between E1A and CBP or p300. This raises the
possibility that suppression of growth inhibition may be
used under appropriate circumstances to determine if a
physical interaction occurs.
The N-terminal/CR1 portions of the Ad3,-4,-5,-9,-12, and
-40 E1A proteins can inhibit yeast growth and this
can be suppressed by CBP
Expression of the N-terminal/CR1 portion of Ad5 E1A
fused to the Gal4p DNA binding domain is sufficient to
inhibit yeast growth (Miller et al., 1995; Shuen et al., 2002).
We constructed vectors expressing the N-terminal/CR1 do-
main of one representative E1A protein from each of the six
Ad subgroups and tested them for their ability to inhibit
yeast growth (Fig. 2). Like Ad5 E1A (subgroup C), the
N-terminal/CR1 portions of Ad9 (subgroup D), Ad4 (sub-
group E), Ad3 (subgroup B), Ad12 (subgroup A), and Ad40
(subgroup F) inhibited yeast growth. The strongest growth
inhibition, reflected by the smallest colony size, was repro-
ducibly observed with the N-terminal/CR1 portion of Ad40
E1A, whose sequence is the least similar to that of Ad5
E1A. These results suggest that the N-terminal/CR1 por-
tions of the E1A proteins of all six human Ad subgroups
share a common cellular target(s) conserved in yeast.
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The results presented in Fig. 1 show that expression of
the E1A binding domain of CBP can restore growth to yeast
expressing full-length Ad5 E1A, likely as a result of a direct
interaction between these two proteins. We tested the effect
of coexpressing this fragment of CBP on growth inhibition
mediated by the N-terminal/CR1 portions of each of the
different Ad E1A proteins (Fig. 2). As expected, coexpres-
sion of residues 1679–1891 of CBP efficiently suppressed
growth inhibition by the N-terminal/CR1 portions of Ad5
and Ad12 E1A, which are known to interact with this region
of CBP (Arany et al., 1995; O’Connor et al., 1999; Lipinski
et al., 1999). Interestingly, this fragment of CBP also sup-
pressed growth inhibition mediated by the N-terminal/CR1
portions of the other E1A proteins (Fig. 2). This suggests
that the E1A proteins of each of the six human Ad sub-
groups physically interact with this portion of CBP.
The N-terminal/CR1 portions of Ad3,-4,-5,-9,-12, and -40
interact with CBP and p300 in vitro
The ability of the various Ad E1A proteins to interact
with CBP and p300 was further assessed in vitro. We
expressed the N-terminal/CR1 portions of the Ad3,-4,-5,-
9,-12 and -40 E1A proteins as fusions to glutathione S-
transferase (GST) and tested their ability to interact with in
vitro transcribed and translated fragments of CBP or p300
(Fig. 3). An interaction was observed between a fragment of
CBP spanning residues 1679–1891 and the N-terminal/CR1
Fig. 1. Effect of CBP and p300 expression on Ad5 E1A-mediated growth inhibition. (A) Map of CBP and the regions that were coexpressed with E1A. The
region spanning residues 1679–1891 has previously been shown to bind Ad5 E1A. (B) Yeast strain w303-1a was transformed with a vector expressing the
full-length Ad5 289 residue E1A protein and vectors expressing the indicated portions of CBP. Transformed yeast were grown for approximately 72 h at 30°C
and photographed. (C) Western blot analysis of the level of E1A protein expression in yeast coexpressing CBP fragments. Cell extracts were prepared as
described under Materials and methods. (D) Yeast were transformed as described in B, except that a vector expressing the portion of p300 spanning residues
1573–1825 was used in place of a vector expressing a portion of CBP.
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portions of all the E1A proteins, but not with GST (Fig. 3A).
A similar result was obtained using a fragment of p300
spanning residues 1573–1825 (Fig. 3B). These in vitro re-
sults confirm the in vivo results shown in Fig. 2 and dem-
onstrate that CBP and p300 are indeed common targets of
each of the different E1A proteins we tested.
Previous characterization of the E1A-CBP interaction
defined a transcriptional adapter motif (TRAM) located
between residues 1811 and 1822 in CBP that is targeted not
only by Ad5 and Ad12 E1A, but also by p53 and E2F-1
(O’Connor et al., 1999). Each of these proteins contains the
consensus sequence FXE/DXXXL (where X is any amino
acid) that was suggested to represent a TRAM binding
motif. With the exception of Ad40 E1A, all the Ad E1A
proteins tested contain an exact TRAM binding sequence,
which is located at the extreme carboxyl edge of CR1. In
Ad40 E1A, which is the most divergent of the E1A proteins
with respect to Ad5 E1A that we tested, the closely related
sequence FPERL-L (where the hyphen represents a gap) is
presumably able to mediate interaction with the TRAM
motif of CBP and the related p300 protein. Interestingly,
Ad41 E1A, the only other member of subgroup F, contains
the sequence FPNWM-L, which diverges even further from
the consensus TRAM binding sequence.
Ad5 E1A-mediated inhibition of yeast growth can be
suppressed by the region of pCAF known
to interact with Ad5 E1A
Like CBP and p300, pCAF is known to interact with the
N-terminal/CR1 portion of Ad5 E1A (Reid et al., 1998),
raising the possibility that it might similarly function to
suppress growth inhibition mediated by Ad5 E1A. We
tested this by cotransforming yeast with vectors expressing
full-length Ad5 E1A and vectors expressing either the
amino (residues 1–352) or the carboxyl (residues 310–832)
portions of pCAF. Yeast coexpressing full-length Ad5 E1A
and residues 1–352 of pCAF continued to grow slowly,
whereas expression of a fragment of pCAF spanning resi-
dues 310 to 832 restored growth to yeast expressing full-
length Ad5 E1A (Fig. 4B). Importantly, residues 310–832
have been previously shown to interact with Ad5 E1A (Reid
et al., 1998), indicating that the portion of pCAF that inter-
acts with the growth inhibitory N-terminal/CR1 portion of
E1A can function like CBP or p300 to suppress E1A func-
tion in yeast. We tested additional C-terminal truncations of
pCAF (Fig. 4A) for suppression of Ad5 E1A-mediated
growth inhibition. Suppression of growth inhibition became
less efficient with progressive truncations, until eventually
no detectable suppression was observed for a fragment of
pCAF spanning residues 310–525 (Fig. 4B). These results
Fig. 2. Effect of CBP expression on growth inhibition mediated by the N-terminal/CR1 portions of representative E1A proteins from each of the six human
adenovirus subgroups. Yeast strain w303-1a was transformed with vectors expressing the N-terminal/CR1 portions of the E1A proteins of Ad3,-4,-5,-9,-12
and -40 with or without a vector expressing a fragment of CBP spanning residues 1679–1891. Transformed yeast were grown for approximately 72 h at 30°C
and photographed. The amino-acid residues present in each test protein fragment are indicated in brackets.
Fig. 3. Interaction of CBP with representative E1A proteins from each of
the six human adenovirus subgroups. The N-terminal/CR1 fragments of
Ad3,-4,-5,-9,-12 and -40 were prepared as recombinant fusions to GST and
used in GST- pull-down assays with an in vitro transcribed and translated
35S-labeled fragment of CBP spanning residues 1679–1891 as described
under Materials and methods. Proteins were recovered with glutathione–
Sepharose and analyzed by SDS-PAGE and radiography. One-tenth of the
input of 35S-labeled proteins used in the binding reactions is shown for
comparison. The amino-acid residues present in each test protein fragment
are indicated in brackets.
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indicate that Ad5 E1A binds to the region of pCAF encom-
passed within residues 310–612.
Growth inhibition by the N-terminal/CR1 portions of the
Ad3,-4,-5,-9,-12, and -40 E1A proteins
can be suppressed by pCAF
The results presented in Fig. 4B and our previous dem-
onstration that expression of a fragment of pCAF (residues
310–832) can restore growth to yeast expressing the N-
terminal/CR1 portion of Ad5 E1A (Shuen et al., 2002)
prompted us to determine the effect of this fragment of
pCAF on growth inhibition mediated by each of the other
Ad E1A proteins. Coexpression of this portion of pCAF
efficiently suppressed growth inhibition by each of the N-
terminal/CR1 portions of the other Ad E1A N-terminal/CR1
fragments, with the exception of Ad40 E1A (Fig. 5A).
However, pCAF was able to weakly suppress growth inhi-
bition mediated by the Ad40 E1A fragment after longer
periods of growth (Fig. 5B). This result suggests that pCAF
can interact with the N-terminal/CR1 regions of the E1A
proteins of six Ad subgroups, although only weakly with Ad
40 E1A.
The N-terminal/CR1 domains of Ad3,-4,-5,-9,-12, and -40
interact with pCAF and yGcn5 in vitro
The ability of the various E1A proteins to interact with
pCAF and its yeast homolog yGcn5 was further assessed in
vitro. We expressed the N-terminal/CR1 portions of the
Ad3,-4, -5,-9,-12 and -40 E1A proteins as fusions to gluta-
thione S-transferase (GST) and tested their ability to interact
with in vitro transcribed and translated fragments of pCAF
or yGcn5 (Fig. 6). An interaction was observed between the
C-terminal fragment of pCAF spanning residues 310–832
(Fig. 6A) or full-length yGcn5 (Fig. 6B) and the N-terminal/
CR1 portions of all the E1A proteins, but not with GST.
These in vitro binding results confirm that pCAF and yGcn5
can bind all the different Ad E1A proteins, although with a
range of affinities. The in vitro interaction of Ad40 E1A
with pCAF or yGcn5 was reproducibly the weakest of all
the Ad E1A proteins tested, supporting our observation that
pCAF could function as only a weak suppressor of growth
inhibition mediated by the N-terminal/CR1 portion of Ad40
E1A (Fig. 5). Interestingly, the interaction with pCAF maps
within the first 29 amino acids of Ad5 E1A (Shuen et al.,
2002) that are only weakly conserved among the different
Fig. 4. Effect of pCAF expression on Ad5 E1A-mediated growth inhibition. (A) Map of pCAF and the regions that were coexpressed with Ad5 E1A. The
region spanning residues 352–695 has previously been reported to bind to Ad5 E1A. (B) Yeast strain w303-1a was transformed with a vector expressing
the full-length Ad5 289 residue E1A protein and vectors expressing the indicated portions of pCAF. Transformed yeast were grown for approximately 72 h
at 30°C and photographed.
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Ad E1A proteins (Avvakumov et al., 2002). Further study
will be required to refine the pCAF interaction region in
E1A and additional comparisons between the different Ad
E1A proteins should aid these investigations.
Our in vitro results confirm that pCAF and its homolog
yGcn5 are indeed common targets of each of the different
E1A proteins we tested. However, the ability of the E1A
proteins to interact with yGcn5 is unlikely to be the sole
determinant of growth inhibition, as Ad40 E1A displayed
the weakest binding to yGcn5 (Fig. 6B), but was reproduc-
ibly the most effective inhibitor of yeast growth (Figs. 2 and
5A). In addition to yGcn5, Ad5 E1A has been shown to bind
the Tra1 component of the yeast SAGA complex (Kulesza
et al., 2002). This interaction likely requires the N-terminal/
CR1 portion of Ad5 E1A, as residues 12–54 are required for
the interaction of E1A with TRAPP, the mammalian ho-
molog of Tra1 (Deleu et al., 2001). Further studies will be
necessary to determine if each of the different Ad E1A
proteins also bind Tra1 and TRAPP.
Growth inhibition by the N-terminal/CR1 portions of the
E1A proteins of all six Ad subgroups requires the SAGA
transcriptional activation complex
The data presented in Fig. 6B show that each of the Ad
E1A proteins is able to interact with the yGcn5 component
Fig. 5. Effect of pCAF expression on growth inhibition mediated by the N-terminal/CR1 portions of representative E1A proteins from each of the six human
adenovirus subgroups. Yeast strain w303-1a was transformed with vectors expressing the N-terminal/CR1 portions of the E1A proteins of Ad3,-4,-5,-9,-12
and -40 with or without a vector expressing a fragment of pCAF spanning residues 310–832. Transformed yeast were grown for approximately 72 h at 30°C
and photographed. (B) Yeast strain w303-1a was transformed with a vector expressing the N-terminal/CR1 portion of Ad40 E1A with or without a vector
expressing the C-terminal portion of pCAF. Yeast were photographed after 7 days of growth at 30°C.
Fig. 6. Interaction of pCAF and yGCN5 with representative E1A proteins
from each of the six human adenovirus subgroups. The N-terminal/CR1
fragments of Ad3,-4,-5,-9,-12 and -40 were prepared as recombinant fu-
sions to GST and tested for interaction with an 35S-labeled fragment of
pCAF spanning residues 310–832 (A) or full-length yGcn5p (B) as de-
scribed in Fig. 3 and under Materials and methods. The amino-acid resi-
dues present in each test protein fragment are indicated in brackets.
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of the SAGA complex in vitro. We and others have previ-
ously shown that growth inhibition mediated by the N-
terminal/CR1 portion of Ad5 E1A requires a functional
SAGA yeast transcriptional activation complex (Kulesza et
al., 2002; Shuen et al., 2002). To determine if the SAGA
complex is required for growth inhibition mediated by each
of the N-terminal/CR1 portions of the other Ad E1A pro-
teins, we analyzed their ability to inhibit growth in a yeast
strain containing a disruption of GCN5 (gcn5). As ex-
pected, the N-terminal/CR1 portion of Ad5 E1A was unable
to inhibit growth in the gcn5 strain. Interestingly, none of
the other Ad E1A proteins inhibited growth in a gcn5
strain although each suppressed growth in an isogenic wild-
type strain (Fig. 7). These in vivo results demonstrate that
the SAGA complex is indeed a target of the E1A proteins of
the six Ad subgroups.
The exact mechanism by which the E1A proteins inhibit
yeast growth in a SAGA-dependent fashion are not known.
Clearly, growth inhibition does not simply result from
blocking the ability of the SAGA complex to modulate
transcription as it is dispensable for yeast viability. How-
ever, growth inhibition by E1A requires a functional com-
plex, as disruption of any of the nonessential components
abrogates growth inhibition by Ad5 E1A (Kulesza et al.,
2002). One possible mechanism could be that E1A is ac-
tively directing the enzymatic activity of this complex to
inappropriate targets. Alternatively, the interaction of E1A
with SAGA may sequester the Tra1 component, which is
essential for yeast viability, preventing it from carrying out
its critical functions. This second explanation is less likely
as E1A can bind Tra1 directly, but the observed effects of
E1A on growth require the entire intact SAGA complex
(Kulesza et al., 2002). Perhaps additional interactions be-
tween E1A and other SAGA components such as yGcn5
effectively stabilize the interaction leading to an effective
sequestration of the essential Tra1 protein.
As to the reasons why the various E1A proteins target
CBP, p300, and pCAF in mammalian cells, one potential
explanation is that they do so simply to disrupt the normal
functions of these acetyltransferases. These proteins typi-
cally function as coactivators for numerous tissue-specific
transcription factors, and disruption of their activities by
Ad5 E1A represses most differentiation-specific gene ex-
pression while maintaining housekeeping and epithelial-
specific gene expression. This is thought to convert the
infected cell into a default phenotype more suitable for the
viral life cycle (Frisch and Mymryk, 2002). Whether similar
alterations in transcription are achieved by the E1A proteins
of other adenovirus serotypes remains to be determined, but
seems likely given their common abilities to target CBP,
p300, and pCAF.
It is also possible that instead of, or in addition to,
disrupting the ability of CBP, p300, or pCAF to function as
coactivators of cellular transcription factors, the E1A pro-
teins may retarget their enzymatic activities to the regula-
tory regions of other genes. This is particularly evident for
Ad12 E1A, which strongly activates the viral E2 transcrip-
tion unit in an N-terminal/CR1-dependent fashion (Brock-
mann and Esche, 2003). Ad12 E1A recruits CBP-dependent
acetyltransferase activity to the E2 promoter by simulta-
neously interacting with the cAMP-response element bind-
ing protein (CREB) and CBP (Fax et al., 2000b). In addi-
tion, Ad12 E1A binding stimulates the acetyltransferase
activity of CBP, leading to a further enhancement of tran-
scription from this viral gene (Fax et al., 2000a).
Importantly, Ad5 E1A has also been shown to recruit
p300 to acetylate pRb, hindering the phosphorylation-de-
pendent regulation of pRb activity by cyclin-dependent ki-
nases (Chan et al., 2001). Interestingly, all of the human or
simian adenovirus E1A proteins that have been sequenced
to date contain a consensus pRb binding motif (Avvakumov
et al., 2002) and could similarly function to enhance acet-
ylation of pRb because we show here that they also bind
p300 and CBP. Additional proteins associated with E1A
Fig. 7. Requirement for the SAGA transcriptional activation complex for growth inhibition by representative E1A proteins from each of the six human
adenovirus subgroups. Wild-type yeast strain FY86 (top) and otherwise isogenic yeast strain FY1370 in which the gene encoding yGcn5 was disrupted
(gcn5; bottom) were transformed with vectors expressing the indicated N-terminal/CR1 portions of the E1A proteins of Ad3,-4,-5,-9,-12 or -40.
Transformed cells were allowed to grow approximately 48 h at 30°C and photographed.
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could similarly be subjected to covalent modification in this
fashion, but this remains to been determined. Binding to
CBP, p300, and pCAF will also likely contribute to the loss
of cell cycle control and transformation by all the E1A
proteins, as mutants of Ad5 E1A that fail to associate with
these proteins are unable to oncogenically transform rodent
cells (Bayley and Mymryk, 1994; Gallimore and Turnell,
2001; Frisch and Mymryk, 2002).
In conclusion, we demonstrate that the E1A proteins of
each of the six human adenovirus subgroups have the re-
markably conserved capacity to bind to the p300, CBP, and
pCAF acetyltransferases in vivo and in vitro despite con-
siderable sequence divergence. In addition, each of the E1A
proteins can functionally interact with the SAGA transcrip-
tional regulatory complex in vivo. Our observation that
these cellular targets are common to all the different E1A
proteins highlights the importance of these interactions for
E1A’s effects on the infected or transformed cell and pro-
vide a genetic system to further explore their consequences.
Materials and methods
Yeast strains, media, and plasmid construction
Yeast strain w303-1A was provided by Dr. Michael
Christman (Boston University, Boston, MA, USA) and used
for all the growth-related experiments except where indi-
cated otherwise. FY86 (wt) and the otherwise isogenic strain
FY1370 that contains a disruption of yGCN5 (gcn5) were
provided by Dr. Chris Brandl (University of Western On-
tario, London, ON, Canada). Yeast culture media were
prepared using standard techniques (Adams et al., 1998).
Yeast expression vectors pRS423 (Christianson et al., 1992)
and pRS423-13S E1A (Zhang et al., 2001), which expresses
the full-length 289 residue Ad5 E1A protein under the
control of the GAL1 promoter, were described previously.
Yeast expression vectors pAS1U, pAS1U-Ad5 1–82,
pGuN, and pGuN-55 have been described previously (Liang
et al., 1995; Shuen et al., 2002). The sequences encoding the
N-terminal/CR1 portions of the E1A proteins of Ad3,-4,-
9,-12 and -40 were PCR amplified with specific oligonucle-
otide primers from DNA templates provided by Drs. A.
Turnell and P. Gallimore (Cancer Research UK Institute for
Cancer Studies, University of Birmingham, Birmingham,
UK), E. Blair (University of Leeds, Leeds, UK), R. Javier
(Baylor College of Medicine, Houston, TX, USA), R. Pad-
manabhan (Georgetown University, Washington, DC,
USA), and J.C. D’Halluin (INSERM U524, Lille Cedex,
France) and subcloned as EcoRI-SalI fragments into pAS1U
and pGEX4T-1 (Amersham Pharmacia Biotech Inc., Baie
d’Urfe´, Que´bec, Canada). For experiments in which the Ad
E1A proteins were coexpressed with CBP, p300, or pCAF,
the coding region for the N-terminal/CR1 portions of Ad3,-
4,-5,-9,-12 and -40 were subcloned into the yeast vector
pRS426-GAL. This plasmid resembles pAS1U except that
it contains the GAL1 rather than the ADH1 regulatory region
controlling expression of the Gal4 DBD. Derivatives of
pJG4-5 (OriGene Technologies Inc., Rockville, MD) ex-
pressing fragments of pCAF, CBP, or p300 were generated
by PCR or the use of convenient restriction digest sites
where possible. Selected portions of pCAF and CBP were
subcloned into pCDNA3.1 (Invitrogen Life Technologies,
Carlsbad, CA, USA) or pCITE-2a (Novagen, Madison, WI,
USA) for in vitro transcription and translation experiments.
T7-yGCN5 (obtained from Dr. P. Walfish, Mount Sinai
Hospital, Toronto, ON, Canada) was used for in vitro tran-
scription and translation of full-length yGcn5.
Growth suppression assay
Yeast transformations were performed using a modified
lithium acetate procedure as described previously (Gietz et
al., 1995). Cells were plated onto appropriate synthetic
complete (SC) omission plates and incubated at 30°C. For
assays of growth inhibition by E1A or E1B, plates were
photographed approximately 48 or 72 h posttransformation
using a Foto/Eclipse Fotodyne gel doc system (Fotodyne
Inc., Hartland, WI, USA) unless otherwise noted in the
figure legends.
Yeast cell extracts and Western blot analysis
Yeast colonies were picked from the SC omission plates
and used to inoculate 5 ml of glucose-supplemented SC liquid
media. Cultures were allowed to grow at 30°C until they
reached an OD600 of 1.0. Yeast cells were collected by cen-
trifugation, washed, resuspended in 5 ml of galactose-supple-
mented SC media, and allowed to grow for an additional 4 h at
30°C. Cultures were then cooled to 4°C, harvested by centrif-
ugation, and washed with 1 ml of cold extraction buffer [200
mM Tris (pH 8.0), 150 mM ammonium sulfate, 10% glycerol,
1 mM EDTA, 2 mM DTT, 1X complete protease inhibitor
cocktail (Roche Diagnostics, Laval, Que´bec, Canada)]. Cell
pellets were resuspended in 100 l of extraction buffer and
vortexed for 1 min in the presence of 200 l of glass beads
followed by incubation on ice for 1 min. This was repeated 5
times, after which supernatants were collected by centrifuga-
tion for 10 min at 4°C. Twenty micrograms of total protein
from each sample were resolved on 10% sodium dodecyl
sulfate–polyacrylamide gels (SDS–PAGE), and E1A proteins
were detected by Western blot analysis with the M73 antibody
(Harlow et al., 1985).
Glutathione S-transferase (GST) pull-downs
GST-E1A fusion proteins were expressed in Escherichia
coli strain BL21 Codon Plus and purified using the protocol
provided by affinity resin manufacturer (Amersham Phar-
macia Biotech Inc., Baie d’Urfe´, Que´bec, Canada). In vitro
translated 35S-labeled methionine full-length yGcn5p, the
carboxyl portion of pCAF spanning amino acids 310–832,
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or a fragment of CBP spanning amino acids 1679–1891
were prepared using the TNT T7 coupled transcription/
translation system (Promega Corp., Madison, WI, USA)
according to the supplied protocol. GST pull-downs were
performed as described previously (Shuen et al., 2002).
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